Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Novo Nordisk logs steepest decline since Aug 2022
Puma slumps after narrowing FY profit outlook
Continental up after Q2 results beat
Just Eat Takeaway top STOXX 600 gainer after rating upgrade
Roche considering divesting $1.9 bln cancer data startup- FT
STOXX 600 up 1.5%
Updated at 1550 GMT
By Ankika Biswas and Pranav Kashyap
Aug 7 (Reuters) -A strong comeback by banks on Wednesday helped Europe's main stock index log its biggest one-day gain since November, even though the continent's largest company by market cap Novo Nordisk slid after trimming its full-year profit outlook.
The pan-European STOXX 600 .STOXX closed 1.5% higher but remained below the key 500-point mark following the recent selloff sparked by U.S. recession fears.
Main indexes in Germany .GDAXI, France .FCHI, London .FTSE and Spain .IBEX also rose 1.5%-2%. Signalling a continued pick-up in investor sentiment, the "fear gauge" volatility index .V2TX fell for a second day from its highest level since March 2022, hit at the start of the week.
Leading sectoral gains, the banking index .SX7P jumped 2.7% to notch its best single-day gain in more than a year, having lost 11% over the past five days, with ABN Amro ABNd.AS jumping 5.6% after raising its full-year net interest income forecast.
Italy's Economy Minister Giancarlo Giorgetti also said the government has no plans to impose additional taxes on bank profits.
European Central Bank policymaker Olli Rehn said rate cuts can continue if confidence in slowing inflation strengthens in the near future.
Data showed a higher-than-expected rise in German industrial production in June, a day after upbeat industrial orders provided some hope for Europe's largest economy as it grapples with a likely recession.
"For the embattled German industrial sector, there was actually some better news," said Elizabeth Martins, senior economist at HSBC.
Notable stock movers included Novo Nordisk NOVOb.CO, which clocked its steepest one-day fall since August 2022, down 6.7%, following a disappointing profit outlook and weaker-than-expected sales of weight-loss drug Wegovy that stirred worries about stiffening competition from Eli Lilly.
German sportswear maker Puma PUMG.DE slumped 10.8% after narrowing its full-year core profit outlook.
Roche ROG.S climbed 3% on a report the Swiss pharmaceutical company is considering divesting cancer data specialist Flatiron Health.
Just Eat Takeaway TKWY.AS jumped 13% after JPMorgan upgraded the online food delivery firm to "overweight" from "neutral".
Continental CONG.DE rose 6.8% on better-than-expected results and guidance for an even stronger second half.
Maersk MAERSKb.CO fell 2.3% after its second-quarter results, with analysts citing higher capital expenditure guidance as one negative factor. It also expects global container shipping growth to slow from this year's strong start.
Reporting by Pranav Kashyap and Ankika Biswas in Bengaluru; Editing by Kirsten Donovan
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
